Medical Developments International Ltd (ASX: MVP) Share Price and News

Mr Hoare is a commercial leader with expertise across multiple Life Science sectors. He is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously, he was Managing Director of Smith & Nephew (S&N) ANZ. He served as President of S&N's Asia Pacific Advanced Wound Management (AWM) business for 5 years and was a member of the Global Executive Management (as one of three Regional Presidents). In his 24 years with S&N, he also held roles in marketing, divisional and general management. His career has also included a senior role at Bristol-Myers Squibb, and as Vice-Chair of the board of Australia's medical device industry body, Medical Technology Association of Australia. Mr Hoare is also the Chair of the People and Culture Committee.

Ms Emmanuel-Donnelly is an experienced IP and business development professional having 35 years of experience locally and internationally. Ms Emmanuel-Donnelly is a former Executive Manager of Business Development and Commercial at the CSIRO, where she led the management of CSIRO's IP team and IP portfolio for 14 years and managed the CSIRO equity portfolio for over 5 years. Prior to this role, Ms Emmanuel-Donnelly was in-house IP Counsel for Unilever in the UK and practised as a patent and trademark attorney for Wilson Gunn (UK), Davies Collison Cave and Griffith Hack in Melbourne. Christine is also currently chairwoman of Impedimed Ltd and non-executive director of Polynovo Ltd (Chair of Remunerations Committee), Pikcha Holdings Ltd, trading as Seminal. She was previously on the Board of the Institute of Patent & Trademarks Attorneys of Australia for 13 years.

Mr Townsend has experience as a global finance executive with a commercial focus and reputation of delivering results across diverse industries, including manufacturing, resources, consumer products and academia. His track record includes business turnarounds, new venture start-ups, mergers and acquisitions across local and global markets, navigating equity and debt capital markets and implementing changes necessary. He is Chair of the Risk Committee.

Dr Basser is a qualified physician, with over 30 years of international medical and biopharmaceutical experience. Dr Basser worked as a medical oncologist in Melbourne prior to joining CSL in 2001. During his 21 years at CSL, he held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. Dr Basser has expertise in international drug and vaccine development and spent several years based in the USA. Dr Basser currently serves as a Non-Executive Director on the Boards of Starpharma Holdings Limited and Doherty Clinical Trials. He has previously served on the Board of the ANZ Breast Cancer Trials Group and the Hadassah Australia Medical Research Collaboration.

Mr Fladrich brings over 30 years of experience in the international pharmaceutical industry. His career includes leadership roles at global companies. He currently also serves as Chair of QBiotics, an Australian unlisted public life sciences company focused on oncology and wound healing therapies. During his executive career, Mr Fladrich was Chief Commercial Officer at Grunenthal, a privately owned German company in pain management. Prior to joining Grunenthal, Mr Fladrich spent 23 years at AstraZeneca. Mr Fladrich held several senior roles there including Vice President Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe.

-

-

-

-

-